Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNTech SE ( (BNTX) ) just unveiled an update.
On May 15, 2026, BioNTech SE held its 2026 Annual General Meeting as a virtual assembly, with 92% of share capital represented and all management proposals approved by a majority of shareholders. The strong turnout and unanimous backing signal broad investor support for the company’s current strategy and governance framework.
As part of a sharpened focus on its expanding late‑stage oncology pipeline, shareholders voted to expand the Supervisory Board from six to eight members and elected Iris Löw‑Friedrich and Susanne Schaffert, both with deep oncology, clinical development and commercialization expertise. Investors also extended the mandates of existing Supervisory Board members Helmut Jeggle, Anja Morawietz and Rudolf Staudigl, and the board subsequently elected Jeggle as its new Chairman, reinforcing continuity while adding specialized leadership as BioNTech advances beyond its COVID‑19 legacy into broader oncology markets.
The most recent analyst rating on (BNTX) stock is a Buy with a $158.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score reflects a strong financial backstop (very low leverage and substantial liquidity, with improved recent free cash flow) but a weak near-term earnings profile (losses and volatile revenues). Technical indicators are bearish with the stock below key moving averages and negative MACD. The latest earnings call supports the medium-term pipeline narrative, but 2026 guidance points to lower revenues and higher spend, keeping the overall score in the mid-range.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next‑generation biopharmaceutical company focused on developing novel investigational therapies for cancer and other serious diseases. Its late‑stage oncology pipeline spans immunomodulators, antibody‑drug conjugates and mRNA cancer immunotherapies, supported by partnerships with major pharma groups including Bristol Myers Squibb, Genentech and Pfizer.
Average Trading Volume: 1,129,545
Technical Sentiment Signal: Sell
Current Market Cap: $23.26B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.